Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia

Schizophrenia Research

Volumn 159, Issue 1, 2014, Pages 51-55

  Song, Xueqin ^a,b,c   Fan, Xiaoduo ^c   Li, Xue ^a   Kennedy, David ^c   Pang, Lijuan ^a   Quan, Meina ^c   Chen, Xumei ^a   Gao, Jinsong ^a   Zhang, Wei ^a   Zhang, Jianjiang ^a   Lv, Luxian ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

BDNF; Folate; Hippocampus; Homocysteine; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FOLIC ACID; HOMOCYSTEINE; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN SIZE; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME METABOLISM; FEMALE; HIPPOCAMPUS; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; VITAMIN BLOOD LEVEL; ADOLESCENT; BLOOD; BLOOD ANALYSIS; IMAGE PROCESSING; IMMUNOASSAY; ORGAN SIZE; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD CHEMICAL ANALYSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLIC ACID; HIPPOCAMPUS; HOMOCYSTEINE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOASSAY; MALE; ORGAN SIZE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84908046123     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.033     Document Type: Article

References (44)

1. Brown A.S., Bottiglieri T., Schaefer C.A., Quesenberry C.P., Liu L., Bresnahan M., Susser E.S. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch. Gen. Psychiatry 2007, 64(1):31-39.
2. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr. Res. 2007, 91(1-3):1-5.
3. Buehlmann E., Berger G.E., Aston J., Gschwandtner U., Pflueger M.O., Borgwardt S.J., Radue E.W., Riecher-Rossler A. Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. J. Psychiatr. Res. 2010, 44(7):447-453.
4. Chen da C., Wang J., Wang B., Yang S.C., Zhang C.X., Zheng Y.L., Li Y.L., Wang N., Yang K.B., Xiu M.H., Kosten T.R., Zhang X.Y. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl.) 2009, 207(3):375-380.
5. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001, 52(1-2):79-86.
6. Ebdrup B.H., Glenthoj B., Rasmussen H., Aggernaes B., Langkilde A.R., Paulson O.B., Lublin H., Skimminge A., Baare W. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J. Psychiatry Neurosci. 2010, 35(2):95-104.
7. Ellison-Wright I., Glahn D.C., Laird A.R., Thelen S.M., Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am. J. Psychiatry 2008, 165(8):1015-1023.
8. Erickson K.I., Prakash R.S., Voss M.W., Chaddock L., Heo S., McLaren M., Pence B.D., Martin S.A., Vieira V.J., Woods J.A., McAuley E., Kramer A.F. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J. Neurosci. 2010, 30(15):5368-5375.
9. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33(3):341-355.
10. Flaum M., O'Leary D.S., Swayze V.W., Miller D.D., Arndt S., Andreasen N.C. Symptom dimensions and brain morphology in schizophrenia and related psychotic disorders. J. Psychiatr. Res. 1995, 29(4):261-276.
11. Frankenburg F.R. The role of one-carbon metabolism in schizophrenia and depression. Harv. Rev. Psychiatry 2007, 15(4):146-160.
12. Glahn D.C., Laird A.R., Ellison-Wright I., Thelen S.M., Robinson J.L., Lancaster J.L., Bullmore E., Fox P.T. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol. Psychiatry 2008, 64(9):774-781.
13. Goff D.C., Bottiglieri T., Arning E., Shih V., Freudenreich O., Evins A.E., Henderson D.C., Baer L., Coyle J. Folate, homocysteine, and negative symptoms in schizophrenia. Am. J. Psychiatry 2004, 161(9):1705-1708.
14. Haidemenos A., Kontis D., Gazi A., Kallai E., Allin M., Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(6):1289-1296.
15. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 2005, 25(2):372-383.
16. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 2005, 162(12):2233-2245.
17. Ikeda Y., Yahata N., Ito I., Nagano M., Toyota T., Yoshikawa T., Okubo Y., Suzuki H. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr. Res. 2008, 101(1-3):58-66.
18. Jindal R.D., Pillai A.K., Mahadik S.P., Eklund K., Montrose D.M., Keshavan M.S. Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr. Res. 2010, 119(1-3):47-51.
19. Kale A., Naphade N., Sapkale S., Kamaraju M., Pillai A., Joshi S., Mahadik S. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res. 2010, 175(1-2):47-53.
20. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 2002, 328(3):261-264.
21. Kim T.H., Moon S.W. Serum homocysteine and folate levels in Korean schizophrenic patients. Psychiatry Investig. 2011, 8(2):134-140.
22. Lewis S.J., Zammit S., Gunnell D., Smith G.D. A meta-analysis of the MTHFR C677T polymorphism and schizophrenia risk. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 135(1):2-4.
23. Lu B. BDNF and activity-dependent synaptic modulation. Learn. Mem. 2003, 10(2):86-98.
24. Lu B., Chow A. Neurotrophins and hippocampal synaptic transmission and plasticity. J. Neurosci. Res. 1999, 58(1):76-87.
25. Martinotti G., Di Iorio G., Marini S., Ricci V., De Berardis D., Di Giannantonio M. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. J. Biol. Regul. Homeost. Agents 2012, 26(3):347-356.
26. Mattson M.P., Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003, 26(3):137-146.
27. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2001, 63(1):71-124.
28. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37(12):1553-1561.
29. Pardon M.C. Role of neurotrophic factors in behavioral processes: implications for the treatment of psychiatric and neurodegenerative disorders. Vitam. Horm. 2010, 82:185-200.
30. Petronijevic N.D., Radonjic N.V., Ivkovic M.D., Marinkovic D., Piperski V.D., Duricic B.M., Paunovic V.R. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(8):1921-1926.
31. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2(1):24-32.
32. Rajarethinam R., DeQuardo J.R., Miedler J., Arndt S., Kirbat R., Brunberg J.A., Tandon R. Hippocampus and amygdala in schizophrenia: assessment of the relationship of neuroanatomy to psychopathology. Psychiatry Res. 2001, 108(2):79-87.
33. Rizos E.N., Rontos I., Laskos E., Arsenis G., Michalopoulou P.G., Vasilopoulos D., Gournellis R., Lykouras L. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(5):1308-1311.
34. Rizos E.N., Papathanasiou M., Michalopoulou P.G., Mazioti A., Douzenis A., Kastania A., Nikolaidou P., Laskos E., Vasilopoulou K., Lykouras L. Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophr. Res. 2011, 129(2-3):201-204.
35. Roffman J.L., Weiss A.P., Purcell S., Caffalette C.A., Freudenreich O., Henderson D.C., Bottiglieri T., Wong D.H., Halsted C.H., Goff D.C. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol. Psychiatry 2008, 63(1):42-48.
36. Runeson B.S., Rich C.L. Diagnostic and statistical manual of mental disorders, 3rd ed. (DSM-III), adaptive functioning in young Swedish suicides. Ann. Clin. Psychiatry 1994, 6(3):181-183.
37. Sartorius A., Hellweg R., Litzke J., Vogt M., Dormann C., Vollmayr B., Danker-Hopfe H., Gass P. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009, 42(6):270-276.
38. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr. Res. 2001, 49(1-2):1-52.
39. Sotiropoulou M., Mantas C., Bozidis P., Marselos M., Mavreas V., Hyphantis T., Antoniou K. BDNF serum concentrations in first psychotic episode drug-naive schizophrenic patients: associations with personality and BDNF Val66Met polymorphism. Life Sci. 2013, 92(4-5):305-310.
40. St Clair D., Xu M., Wang P., Yu Y., Fang Y., Zhang F., Zheng X., Gu N., Feng G., Sham P., He L. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA 2005, 294(5):557-562.
41. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2003, 8(6):592-610.
42. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., Weinberger D.R., Kleinman J.E. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2005, 10(7):637-650.
43. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 2000, 157(1):16-25.
44. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., Chen da C., Kosten T.R., Zhang X.Y. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(8):1508-1512.